Skip to main content
. 2012 Dec 3;7:5941–5956. doi: 10.2147/IJN.S35556

Figure 6.

Figure 6

Cytotoxicity + against epimastigote forms of Trypanosoma cruzi measured after 24 hours treatment with actinomycin D contained in functionalized nanocapsules bound to IgGs. (A) Epimastigotes of T. cruzi treated with 50 ng/mL of actinomycin D. (B) Epimastigotes of T. cruzi treated with ISCOM-9-actinomycin D-A-IgGsp containing 0.15 × 10−2 ng/mL of actinomycin D. (C) Epimastigotes of T. cruzi treated with ISCOM-9-actinomicyn D-A-IgGsp containing 2.88 × 10−2 ng/mL of actinomycin D. (D) Epimastigotes of T. cruzi treated with ISCOM-9- actinomycin D-A-IgGsp containing 5.76 × 10−2 ng/mL of actinomycin D. (E) Control culture of untreated epimastigote forms of T. cruzi. (F) Control culture of epimastigote forms of T. cruzi treated with functionalized nanocapsules without actinomycin D ISCOM-9-matrix A-IgG specific against the parasite.

Notes: The results are the mean of three experiments ± standard error of the mean. ns = P > 0.05; ***P < 0.001 Tukey–Kramer multiple comparisons test.

Abbreviations: IgG, immunoglobulin; ISCOM, immunostimulating complex; ns, not significant.